Alphatec Holdings Reports 30% Revenue Growth to $196.5 Million in Latest Quarter

Alphatec Holdings, Inc. reported significant financial performance improvements in its latest quarterly filing, with total revenue from products and services reaching $196.5 million for the three months ended September 30, 2025, a 30% increase from $150.7 million in the same period last year. For the nine months ended September 30, 2025, revenue rose to $551.2 million, up 27% from $434.8 million in 2024. The growth was attributed to increased product volume driven by a larger surgeon user base and the expansion of the company’s product portfolio.

Despite the revenue growth, Alphatec recorded a net loss of $28.6 million for the third quarter, an improvement from a net loss of $39.6 million in the prior year. For the nine-month period, the net loss was $121.6 million, compared to $128.8 million in 2024. The company’s operating expenses increased by 12% to $153.2 million for the quarter, primarily due to higher sales, general, and administrative costs, which rose by 14% to $124.3 million. Litigation-related expenses also surged, reflecting ongoing legal matters.

In terms of strategic developments, Alphatec issued $405 million in 0.75% senior convertible notes due in 2030, with net proceeds used for general corporate purposes and to repurchase 80% of its 2026 convertible notes. The company also reported a cash balance of $155.7 million as of September 30, 2025, up from $138.8 million at the end of 2024. This increase in cash was supported by positive cash flow from operating activities, which generated $24.5 million during the nine months, a significant turnaround from a cash outflow of $55.2 million in the same period last year.

Operationally, Alphatec's product adoption rates have improved, with a notable increase in customer engagement metrics. The company reported a growing surgeon user base, which has contributed to its revenue growth. The U.S. market remains the primary revenue driver, accounting for $184.4 million in the third quarter, while international sales also saw an increase, reaching $12.1 million. The company continues to focus on expanding its geographic footprint and enhancing its product offerings to capture a larger market share.

Looking ahead, Alphatec remains optimistic about its growth trajectory, emphasizing its commitment to innovation in spinal surgery technology. The company plans to continue investing in its product development and sales capabilities to further penetrate existing markets and explore new opportunities. However, it acknowledges the potential need for additional funding to support its growth initiatives and maintain liquidity as it navigates the evolving healthcare landscape.